We grow Innovation
Meet our experienced team of executives and consultants who drive our company forward with their expertise.
We grow Innovation
Meet our experienced team of executives and consultants who drive our company forward with their expertise.
Management
Advisory-Board

Prof. Dr.
Ascher Shmulewitz M.D.
joined in January 2023. He has over 30 years of experience as a life science scientist and more than 25 years of experience leading and expanding biopharma companies in the USA, Europe, and Israel. Particularly noteworthy is his long-standing collaboration with the late Raphael Mechoulam, a pioneer of cannabis research.

Prof. Dr.
Markus Veit Pharm. D.
who also joined in January 2023, is a member of the German Pharmacopoeia Expert Committee at BfArM and was involved more than 200 approvals of medicines in Europe and the US in his over 25-year career. His expertise lies in the areas of pharmaceutical development, testing, and regulatory affairs. His key expertise covers any aspects related to herbal medicinal products.

Dr.
Christian Rybak
has been part of the board since November 2022. He is a renowned attorney and partner at Ehlers & Partner. With his international reputation in strategic and health policy consulting, particularly in Germany, he brings a wide range of expertise to the team. Additionally, he is a lecturer at the University of Bayreuth (health law) and the University of Münster (School of Tax and Business Law).

Héctor Jausas
also a member of the board since November 2022, has over 25 years of experience in the pharmaceutical sector as a lawyer, partner, and head of Fieldfisher's Life Sciences Department. He is a member and former partner of Conferénce Bleue and a corresponding member of the Royal Academy of Pharmacy of Catalonia.

Rupert Jason Haynes
has been on board since May 2023. He is an expert in the bioindustry with leading roles at companies like GW Pharmaceuticals, where he played a significant role in the development of products like Epidiolex. Currently, he heads the research and development at Sapient Therapeutics and is a co-founder of Diligenc Capital Ltd. He has a BSc in Biology from Oxford Brookes University.